Rexahn Awarded Patent in Japan

Rexahn Pharmaceuticals, Inc.

today announced that it was awarded patent 4,546,454 entitled, “Antisense Oligonucleotides that Inhibit Expression of HIF-1,” by the Japanese Patent Office.